Tomasz Urasinski
Overview
Explore the profile of Tomasz Urasinski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
577
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Troschke T, Wieczorek A, Kulinski K, Ociepa T, Zielezinska K, Lode H, et al.
Healthcare (Basel)
. 2023 May;
11(10).
PMID: 37239717
This article reports on the development, implementation and management of a German-Polish telemedicine network in the field of pediatric oncology and hematology in the Euroregion Pomerania. The achievements and challenges...
12.
Urasinski T, Paczoska K, Badowska W, Bobrowska H, Dakowicz L, Dobaczewski G, et al.
Front Pediatr
. 2023 Mar;
11:1084539.
PMID: 36911027
Introduction: In 2020, the new nationwide protocol of prophylaxis in Polish plasma-derived FVIII (pdFVIII) previously treated patients (PTPs) with severe hemophilia A (sHA) was introduced, resulting in the necessity of...
13.
Czogala M, Czogala W, Pawinska-Wasikowska K, Ksiazek T, Bukowska-Strakova K, Sikorska-Fic B, et al.
Cancers (Basel)
. 2023 Feb;
15(3).
PMID: 36765692
Acute P./myeloid leukemia post cytotoxic therapy (AML-pCT) is rare complication of cancer treatment in childhood. The objective of the study was to identify clinical characteristics and provide an analysis of...
14.
Tomaszewska N, Strzemecka J, Krolak A, Zielezinska K, Laguna P, Pajak J, et al.
Haemophilia
. 2022 Nov;
29(1):367-369.
PMID: 36399358
No abstract available.
15.
Zawitkowska J, Drabko K, Czyzewski K, Dziedzic M, Jaremek K, Zalas-Wiecek P, et al.
Pathogens
. 2022 Oct;
11(10).
PMID: 36297147
Viral infections can be a serious complication of therapy in children with acute lymphoblastic leukemia (ALL). In this study, we focused on the incidence and the profile of viral infection...
16.
Samborska M, Baranska M, Wachowiak J, Skalska-Sadowska J, Thambyrajah S, Czogala M, et al.
Front Oncol
. 2022 Jul;
12:935373.
PMID: 35875115
Introduction: Myeloid sarcoma (MS) is an extramedullary malignant tumor composed of immature myeloid cells. It occurs in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myeloid leukemia...
17.
Latoch E, Zubowska M, Mlynarski W, Stachowicz-Stencel T, Stefanowicz J, Slawinska D, et al.
Cancer Epidemiol
. 2022 Jul;
80:102209.
PMID: 35868173
Background: The effect of age on the incidence of late sequelae that occur after anticancer treatment in childhood is still not fully elucidated. In this multicenter study of long-term survivors...
18.
Slota L, Sedek L, Kulis J, Perkowski B, Malinowska I, Zawitkowska J, et al.
Cent Eur J Immunol
. 2022 May;
47(1):84-91.
PMID: 35600149
Flow cytometry (FCM) is a precise and well-established tool to assess the minimal residual disease (MRD) level in childhood acute lymphoblastic leukemia (ALL). It is crucial to distinguish leukemic cells...
19.
Czogala M, Balwierz W, Pawinska-Wasikowska K, Ksiazek T, Bukowska-Strakova K, Czogala W, et al.
Cancers (Basel)
. 2021 Sep;
13(18).
PMID: 34572762
Background: From 1983, standardized therapeutic protocols for pediatric acute myeloid leukemia (AML) based on the BFM group experience were introduced in Poland. We retrospectively analyzed the results of pediatric AML...
20.
Zawitkowska J, Lejman M, Romiszewski M, Matysiak M, Cwiklinska M, Balwierz W, et al.
Sci Rep
. 2020 Nov;
10(1):20168.
PMID: 33214594
The aim of the study was to retrospectively compare the effectiveness of the ALL IC-BFM 2002 and ALL IC-BFM 2009 protocols and the distribution of risk groups by the two...